Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019 - P&T Community
[unable to retrieve full-text content] NAVIGATING THE SILENCE: RECONSIDERING TREATMENT PARADIGMS IN ASYMPTOMATIC SEVERE AORTIC STENOSIS ScienceDirect.com
[unable to retrieve full-text content] High arrhythmic risk in antero-septal acute myocardial ischemia is explained by increased transmural reentry occurrence | Scientific Reports Nature
Comments
Post a Comment